VITA OSTEO SUPPORT
Nutritional support for bone health
Price: $54.99 (USA Only)
DESCRIPTION
Vita Osteo Support is a dietary supplement with highly absorbable
calcium, vitamin K, magnesium, zinc, copper, manganese, boron,
vitamin D, horsetail, betaine, ipriflavone, and soy isoflavones
that provides outstanding nutritional support for bone structure
and function.
FUNCTIONS
The adult human body contains approximately 1,200 g of calcium,
about 99% of which is present in the
skeleton. Bone is constantly turning over, a continuous process
of formation and resorption. In children and
adolescents, the rate of formation of bone mineral predominates
over the rate of resorption. Once one
reaches peak bone mass, sometime between the age of 20 and 30,
bone formation slows down and bone
resorption begins to prevail over bone formation, beginning the
cycle of progressive, age-associated bone
demineralization. Therefore, in normal aging, there is a gradual
loss of bone.
The condition of reduced bone mineral density can increase risk
of fractures and affects a large proportion
of the elderly in developed countries. Caucasian and Asian women
typically have low peak bone densities,
and therefore, are at the greatest risk of fractures in later
life. It is generally accepted that obtaining enough
dietary calcium throughout life can significantly decrease the
risk of fractures due to reduced bone
density. Among other factors, such as regular exercise, gender
and race, calcium supplementation during
childhood and adolescence appears to be a prerequisite for maintaining
adequate bone density later in life. But even the elderly can
benefit significantly from supplementation with dietary calcium.
In women, bone loss is generally accelerated following menopause.
The decline in estrogen levels associated with menopause appears
to put women at increased risk for declining bone density and
associated fractures.
Ipriflavone, derived from naturally occurring isoflavones, promotes
bone density by inhibiting bone
resorption. Numerous studies of postmenopausal women and individuals
whose bones are showing signs
of demineralization have investigated the benefits of ipriflavone
on bone health. Laboratory and clinical
studies have documented ipriflavones positive effect on bone
density. Experts agree that ipriflavone appears to directly inhibit
osteoclast activity, thereby decreasing bone resorption.
Scientists suspect ipriflavone may also stimulate osteoblast activity.
Since osteoblasts are responsible for
laying down new bone, an increase in osteoblast activity would
result in increased bone mineralization. This suggests ipriflavone
may not only inhibit the breakdown of existing bone, but also
encourage the formation of new bone.
In addition, Vita Osteo Support contains soy isoflavone concentrate.
Isoflavones from soy, including
genistein and daidzein are a class of phytoestrogens, plant-derived
compounds that are similar in structure
and/or function to animal estrogens. Epidemiological studies have
found that individuals with high soy intakes often enjoy certain
health advantages. Numerous laboratory and clinical studies, investigating
the health benefits of soy products, have identified soy isoflavones
as key components responsible for the health benefits associated
with soy foods. Isoflavones have both weak estrogenic and anti-estrogenic
activity, which may contribute to their ability to moderate menopausal
symptoms and support maintenance of bone mineral density. Isoflavones
also help protect the cardiovascular system, support the immune
system, inhibit angiogenesis, and protect against oxidative damage
as antioxidants.
INDICATIONS
Vita Osteo Support may be a useful dietary supplement for those
who wish to support the healthy functioning of their bone structure.
DOSAGE
Each 2 Tablets Contains:
ฎ
Calcium (from Calcium Citrate/Carbonate
Complex) ......................................................1200
mg
Vitamin D .......................................................200
I.U.
Vitamin K
.....100 mg
Magnesium oxide and citrate
..
.400 mg
Zinc
10 mg
Copper
.1 mg
Manganese (chelated)
.
.5 mg
Ipriflavone
...200 mg
Soy bean extract..............................................250
mg
(standardized 2.5-3.5% flavanoids)
Boron citrate...
1 mg
Horsetail
..
100 mg
Betaine HCl
25 mg
SUGGESTED USE
Adults take 2 tablets daily or as directed by physician.
SIDE EFFECTS
No adverse effects have been reported
STORAGE
Store in a cool, dry place, away from direct light. Keep out of
reach of children.
References
Adami S, Bufalino L, Cervetti R, Di Marco C, Di Munno O, Fantasia
L,
Isaia GC, Serni U, Vecchiet L, Passeri M.
Ipriflavone prevents radial bone loss in postmenopausal women
with low
bone mass over 2 years. Osteoporos Int 1997;7:119-25.
Adlercreutz H, Mazur W. Phyto-oestrogens and Western diseases.
Ann
Med 1997;29:95-120.
Agnusdei D, Adami S, Cervetti R, Crepaldi G, Di Munno O, Fantasia
L,
Isaia GC, Letizia G, Ortolani S, Passeri M, et al. Effects of
ipriflavone on
bone mass and calcium metabolism in postmenopausal osteoporosis.
Bone Miner 1992;19 Suppl 1:S43-8.
Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, De
Aloysio D.
The effect of dietary soy supplementation on hot flushes. Obstet
Gynecol
1998;91:6-11.
Bendich A, Leader S, Muhuri P. Supplemental calcium for the prevention
of hip fracture: potential health-economic benefits. Clin Ther
1999;21:1058-72.
Benvenuti S, Petilli M, Frediani U, Tanini A, Fiorelli G, Bianchi
S,
Bernabei PA, Albanese C, Brandi ML. Binding and bioeffects of
Ipriflavone on a human preosteoclastic cell line. Biochem Biophys
Res
Commun 1994;201:1084-9.
Bronner F. Calcium and osteoporosis. Am J Clin Nutr 1994;60:831-6.
Bronner F, Pansu D. Nutritional aspects of calcium absorption.
J Nutr
1999;129:9-12.
Castelo-Branco C. Management of osteoporosis. An overview. Drugs
Aging 1998;12:25-32.
Cheng SL, Zhang SF, Nelson TL, Warlow PM, Civitelli R. Stimulation
of human osteoblast differentiation and function by ipriflavone
and its
metabolites. Calcif Tissue Int 1994;55:356-62.
Civitelli R. In vitro and in vivo effects of ipriflavone on bone
formation
and bone biomechanics. Calcif Tissue Int 1997;61:S12-4.
Civitelli R, Abbasi-Jarhomi SH, Halstead LR, Dimarogonas A.
Ipriflavone improves bone density and biomechanical properties
of adult
male rat bones. Calcif Tissue Int 1995;56:215-9.
de Aloysio D, Gambacciani M, Altieri P, Ciaponi M, Ventura V,
Mura
M, Genazzani AR, Bottiglioni F. Bone density changes in
postmenopausal women with the administration of ipriflavone alone
or in
association with low-dose ERT. Gynecol Endocrinol 1997;11:289-93.
Gambacciani M, Cappagli B, Piaggesi L, Ciaponi M, Genazzani AR.
Ipriflavone prevents the loss of bone mass in pharmacological
menopause
induced by GnRH-agonists. Calcif Tissue Int 1997;61:S15-8.
Gambacciani M, Ciaponi M, Cappagli B, Piaggesi L, Genazzani AR.
Effects of combined low dose of the isoflavone derivative ipriflavone
and
estrogen replacement on bone mineral density and metabolism in
postmenopausal women. Maturitas 1997;28:75-81.
Gennari C, Adami S, Agnusdei D, Bufalino L, Cervetti R, Crepaldi
G, Di
Marco C, Di Munno O, Fantasia L, Isaia GC, Mazzuoli GF, Ortolani
S,
Passeri M, Serni U, Vecchiet L. Effect of chronic treatment with
ipriflavone in postmenopausal women with low bone mass. Calcif
Tissue
Int 1997;61:S19-22.
Gennari C, Agnusdei D, Crepaldi G, Isaia G, Mazzuoli G, Ortolani
S,
Bufalino L, Passeri M. Effect of ipriflavone--a synthetic derivative
of
natural isoflavones-- on bone mass loss in the early years after
menopause. Menopause 1998;5:9-15.
Meunier PJ, Delmas PD, Eastell R, McClung MR, Papapoulos S, Rizzoli
R, Seeman E, Wasnich RD. Diagnosis and management of osteoporosis
in postmenopausal women: clinical guidelines. International Committee
for Osteoporosis Clinical Guidelines. Clin Ther 1999;21:1025-44.
Nardo F, Scrofani V, Costa G, Bellanca S, Petrovec MM, Clemenza
F,
Licciardello S. [Therapeutic protocols compared in the treatment
of
postmenopausal osteoporotic disease]. Minerva Ginecol 1994;46:305-15.
Nozaki M, Hashimoto K, Inoue Y, Ogata R, Okuma A, Nakano H.
Treatment of bone loss in oophorectomized women with a combination
of ipriflavone and conjugated equine estrogen. Int J Gynaecol
Obstet
1998;62:69-75.
O'Brien KO. Combined calcium and vitamin D supplementation reduces
bone loss and fracture incidence in older men and women. Nutr
Rev
1998;56:148-50.
Ohta H, Komukai S, Makita K, Masuzawa T, Nozawa S. Effects of
1-
year ipriflavone treatment on lumbar bone mineral density and
bone
metabolic markers in postmenopausal women with low bone mass.
Horm
Res 1999;51:178-83.
Petilli M, Fiorelli G, Benvenuti S, Frediani U, Gori F, Brandi
ML.
Interactions between ipriflavone and the estrogen receptor. Calcif
Tissue
Int 1995;56:160-5.
Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW, Jr.
Soy protein and isoflavones: their effects on blood lipids and
bone density
in postmenopausal women. Am J Clin Nutr 1998;68:1375S-1379S.
Reid IR. The roles of calcium and vitamin D in the prevention
of
osteoporosis. Endocrinol Metab Clin North Am 1998;27:389-98.
